Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12801376 | 0.67 | PI4KA (0.64) | — | |
| SCHEMBL5142438 | 0.63 | PRMT5 (0.49) | — | |
| SCHEMBL20419925 | 0.63 | ALDH1A1 (0.45) | NLRP3 | |
| SCHEMBL17817478 | 0.62 | ALDH1A1 (0.54) | — | |
| SCHEMBL12292376 | 0.58 | ALDH1A1 (0.56) | — | |
| SCHEMBL10071455 | 0.57 | DGKA (0.56) | NLRP3 | |
| SCHEMBL10071453 | 0.57 | DGKA (0.56) | NLRP3 | |
| SCHEMBL10071462 | 0.56 | DGKA (0.55) | NLRP3 | |
| SCHEMBL10071460 | 0.56 | DGKA (0.55) | NLRP3 | |
| SCHEMBL17318241 | 0.55 | TLR4 (0.51) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081462-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | NLRP3 1317/4885 |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | NLRP3 1317/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | NLRP3 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.